bluuebunny/crossref_metadata_2025_split huggingface dataset:
Effect of duloxetine in patients with fibromyalgia: tiredness subgroups
Authors: Bradley Laurence A , Bennett Robert , Russell Irwin J , Wohlreich Madelaine M , Chappell Amy S , Wang Fujun , D'Souza Deborah N , Moldofsky Harvey 
Published: July 2010

Abstract
Introduction
This study tested the hypothesis that baseline ratings of fatigue/tiredness would be negatively associated with the efficacy of duloxetine on measures of pain and functional ability in patients with fibromyalgia.

Methods
A post hoc analysis of pooled data from 4 double-blind, placebo-controlled studies of duloxetine in fibromyalgia was performed. The fibromyalgia impact questionnaire (FIQ) tiredness item score (0 to 10 scale) was used to define tiredness subgroups. Patients were stratified into 3 subgroups: mild (0 to 3), moderate (4 to 6), and severe (7 to 10) tiredness. Analysis of covariance models and logistic regressions were used to test treatment-by-tiredness subgroup interactions.

Results
Data from the first 3 months are included in this post hoc analysis (duloxetine N = 797, placebo N = 535). At baseline, the distribution of tiredness severity in the duloxetine and placebo groups respectively was 3.64% and 3.75% mild, 16.71% and 15.57% moderate, and 79.65% and 80.68% severe. Rates of clinically significant (≥30% and ≥50%) improvement in brief pain inventory (BPI) average pain were similar across the tiredness subgroups. Tiredness severity at baseline was not negatively associated with the effects of duloxetine on patients' reports of functional ability using the FIQ total score, FIQ measures of physical impairment, interference with work, pain, stiffness, and depression and the medical outcomes study short form-36 (SF-36).

Conclusions
Studies of duloxetine in fibromyalgia have demonstrated clinically significant improvements in pain and functional ability (FIQ, SF-36). This post hoc analysis of data shows that the efficacy of duloxetine among patients with fibromyalgia does not vary as a function of baseline ratings of fatigue/tiredness.
Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients
Authors: Oberkofler Christian E , Dutkowski Philipp , Stocker Reto , Schuepbach Reto A , Stover John F , Clavien Pierre-Alain , Béchir Markus 
Published: July 2010

Abstract
Introduction
The impact of model of end stage liver disease (MELD) score on postoperative morbidity and mortality is still elusive, especially for high MELD. There are reports of poorer patient outcome in transplant candidates with high MELD score, others though report no influence of MELD score on outcome and survival.

Methods
We retrospectively analyzed data of 144 consecutive liver transplant recipients over a 72-month period in our transplant unit, from January 2003 until December 2008 and performed uni- and multivariate analysis for morbidity and mortality, in particular to define the influence of MELD to these parameters.

Results
This study identified MELD score greater than 23 as an independent risk factor of morbidity represented by intensive care unit (ICU) stay longer than 10 days (odds ratio 7.0) but in contrast had no negative impact on mortality. Furthermore, we identified transfusion of more than 7 units of red blood cells as independent risk factor for mortality (hazard ratio 7.6) and for prolonged ICU stay (odds ratio [OR] 7.8) together with transfusion of more than 10 units of fresh frozen plasma (OR 11.6). Postoperative renal failure is a strong predictor of morbidity (OR 7.9) and postoperative renal replacement therapy was highly associated with increased mortality (hazard ratio 6.8), as was hepato renal syndrome prior to transplantation (hazard ratio 13.2).

Conclusions
This study identified MELD score greater than 23 as an independent risk factor of morbidity represented by ICU stay longer than 10 days but in contrast had no negative impact on mortality. This finding supports the transplantation of patients with high MELD score but only with knowledge of increased morbidity.
Identification of a bone marrow-derived CD8αα+ dendritic cell-like population in inflamed autoimmune target tissue with capability of inducing T cell apoptosis
Authors: Wu Jean , Zhou Cindy , Robertson Julie , Weng Connie C Y , Meistrich Marvin L , Tailor Ramesh C , Lou Ya-Huan 
Published: July 2010

Abstract
Special dendrictic cells invade target tissue at late autoimmune inflammation stage and may terminate inflammation by induction of T cell apoptosis.
DCs play critical roles in promotion of autoimmunity or immune tolerance as potent APCs. In our anti-GBM GN model, WKY rats develop severe T cell-mediated glomerular inflammation followed by fibrosis. A DC-like cell population (CD8αα+CD11c+MHC-II+ED1–) was identified in the inflamed glomeruli. Chimera experiments demonstrated that the CD8αα+ cells were derived from BM. The CD8αα+ cells infiltrated glomeruli at a late stage (Days 28–35), coincident with a rapid decline in glomerular inflammation before fibrosis. The CD8αα+ cells isolated from inflamed glomeruli were able to migrate rapidly from the bloodstream into inflamed glomeruli but not into normal glomeruli, suggesting that the migration was triggered by local inflammation. Despite high-level expression of surface and cellular MHC class II molecules, in vitro experiments showed that this CD8αα+ DC-like cell induced apoptosis but not proliferation in antigen-specific CD4+ T cells from T cell lines or freshly isolated from lymph nodes; they were not able to do so in the absence of antigens, suggesting induction of apoptosis was antigen-specific. Furthermore, apoptotic T cells were detected in a large number in the glomeruli at Day 32, coincident with the infiltration of the cells into glomeruli, suggesting that the cells may also induce T cell apoptosis in vivo. A potential role of this CD8αα+ DC-like population in peripheral immune tolerance and/or termination of autoimmune inflammation was discussed.
The role of interferon-γ in the pathogenesis of acute intra-abdominal sepsis
Authors: Romero Christopher R , Herzig Daniela S , Etogo Anthony , Nunez Jesus , Mahmoudizad Rod , Fang Geping , Murphey E D , Toliver-Kinsky Tracy , Sherwood Edward R 
Published: July 2010

Abstract
IFNγ produced by intraperitoneal myeloid and NK cells during cecal ligation/puncture-induced septic shock facilitates myeloid cell activation yet blockade of IFNγ does not improve survival.
Several studies indicate that IFN-γ facilitates systemic inflammation during endotoxin-induced shock. However, the pathobiology of IFN-γ in clinically relevant models of septic shock, such as CLP, is not well understood. In this study, the role of IFN-γ in the pathogenesis of CLP-induced septic shock was evaluated by examining IFN-γ production at the tissue and cellular levels. The impact of IFN-γ neutralization on systemic inflammation, bacterial clearance, and survival was also determined. Following CLP, concentrations of IFN-γ in plasma and peritoneal lavage fluid were low in comparison with concentrations of IL-6 and MIP-2, as was IFN-γ mRNA expression in liver and spleen. The overall percentage of IFN-γ+ splenocytes was &lt;5% after CLP and not statistically different from control mice. Intracellular IFN-γ was present in a large proportion of peritoneal exudate cells after CLP, primarily in infiltrating myeloid cells and NK cells. i.p. myeloid cell activation was decreased in IFN-γKO mice, and plasma concentrations of IL-6 and MIP-2 were significantly lower in IFN-γKO mice and in mice treated with anti-IFN-γ compared with controls, but bacterial clearance was not affected. IFN-γKO mice were resistant to CLP-induced mortality when treated with systemic antibiotics. However, neutralization of IFN-γ with blocking antibodies did not improve survival significantly. These studies show that IFN-γ facilitates the proinflammatory response during CLP-induced septic shock. However, neutralization of IFN-γ did not improve survival uniformly.
Randomized Clinical Trial of Telephone-Administered Cognitive-Behavioral Therapy to Reduce Post-Traumatic Stress Disorder and Distress Symptoms After Hematopoietic Stem-Cell Transplantation
Authors: DuHamel Katherine N. , Mosher Catherine E. , Winkel Gary , Labay Larissa E. , Rini Christine , Meschian Yeraz Markarian , Austin Jane , Greene Paul B. , Lawsin Catalina R. , Rusiewicz Anna , Grosskreutz Celia L. , Isola Luis , Moskowitz Craig H. , Papadopoulos Esperanza B. , Rowley Scott , Scigliano Eileen , Burkhalter Jack E. , Hurley Karen E. , Bollinger Andreas R. , Redd William H. 
Published: July 2010

Purpose A significant number of survivors of hematopoietic stem-cell transplantation (HSCT) report enduring adverse effects of treatment, including illness-related post-traumatic stress disorder (PTSD) symptoms and general distress. We report results of a randomized clinical trial that tested the effects of a 10-session, telephone-administered cognitive-behavioral therapy (CBT) intervention on PTSD, depression, and distress symptoms. Methods Survivors who had undergone HSCT 1 to 3 years earlier (N = 408) were assessed for study eligibility. Those who met study eligibility criteria (n = 89) completed a baseline assessment that included a clinical interview and self-report measures of PTSD symptoms (the primary outcome) and depression and general distress (the secondary outcomes). Next, they were randomly assigned to CBT or an assessment-only condition. Survivors in the CBT group completed 10 individual telephone-based CBT sessions (T-CBT) that included strategies to reduce PTSD symptoms, depression, and general distress. Follow-up assessments occurred at 6, 9, and 12 months after the baseline assessment. Results Linear mixed-model analyses revealed that, compared with HSCT survivors in the assessment-only condition, survivors who completed T-CBT reported fewer illness-related PTSD symptoms, including less avoidance (P < .001) and fewer intrusive thoughts (P < .05) as well as less general distress and fewer depressive symptoms (P < .05) even after controlling for potential demographic and medical covariates. These results were consistent across the three follow-up assessments. Conclusion A brief, telephone-administered CBT intervention developed for HSCT survivors is an efficacious treatment for reducing illness-related PTSD symptoms and general distress.
Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study
Authors: Mauz-Körholz Christine , Hasenclever Dirk , Dörffel Wolfgang , Ruschke Kathrin , Pelz Tanja , Voigt Antje , Stiefel Martina , Winkler Melanie , Vilser Constanze , Dieckmann Karin , Karlén Jonas , Bergsträsser Eva , Fosså Alexander , Mann Georg , Hummel Michael , Klapper Wolfram , Stein Harald , Vordermark Dirk , Kluge Regine , Körholz Dieter 
Published: July 2010

Purpose Vincristine, etoposide, prednisone, and doxorubicin (OEPA)–cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDAC) is derived from standard vincristine, procarbazine, prednisone, and doxorubicin (OPPA)–cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) chemotherapy by replacing procarbazine with etoposide and dacarbazine for a potentially less gonadotoxic regimen for boys with Hodgkin's lymphoma (HL). Patients and Methods Five hundred seventy-three pediatric patients with classical HL were enrolled onto the German Society of Pediatric Oncology and Hematology–Hodgkin's Disease (GPOH-HD) -2002 study between November 2002 and December 2005. Boys received two courses of OEPA and girls received two courses of OPPA for induction. Treatment group (TG) -2 (intermediate stages) and TG-3 (advanced stages) patients received further two or four cycles COPP (girls) or COPDAC (boys), respectively. After chemotherapy all patients received involved-field irradiation with 19.8 Gy, except for patients with early-stage disease (TG-1) in complete remission. Results Five hundred seventy-three patients (287 males and 286 females) were less than 18 years old and fulfilled all inclusion criteria; 195 patients (34.0%) were allocated to TG-1, 139 (24.3%) were allocated to TG-2, and 239 (41.7%) were allocated to TG-3. Toxicity of OEPA-COPDAC was tolerable overall. Hematotoxicity was more pronounced with OEPA than OPPA, whereas it was less pronounced with COPDAC compared with COPP. The median observation time was 58.6 months. Overall survival and event-free survival (EFS) rates (± SE) at 5 years were 97.4% ± 0.7% and 89.0% ± 1.4%, respectively. In TG-1, overall EFS was 92.0% ± 2.0%. EFS of patients without irradiation (93.2% ± 3.3%) was similar to that of irradiated patients (91.7% ± 2.5%), confirming results of the previous GPOH-HD-95 study. In TG-2+3, EFS did not significantly differ between boys and girls (90.2% ± 2.3 v 84.7% ± 2.7, respectively; P = .12). Conclusion In TG-2+3, results in boys and girls are superimposable. OPPA-COPP and OEPA-COPDAC seem to be exchangeable regimens in intermediate- and advanced-stage classical HL in pediatric patients.
High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma
Authors: Morschhauser Franck , Kraeber-Bodéré Françoise , Wegener William A. , Harousseau Jean-Luc , Petillon Marie-Odile , Huglo Damien , Trümper Lorenz H. , Meller Johannes , Pfreundschuh Michael , Kirsch Carl-Martin , Naumann Ralph , Kropp Joachim , Horne Heather , Teoh Nick , Le Gouill Steven , Bodet-Milin Caroline , Chatal Jean-Francois , Goldenberg David M. 
Published: July 2010

Purpose Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL). Patients and Methods A multicenter trial evaluated two or three weekly infusions of yttrium-90 (90Y) epratuzumab tetraxetan (humanized anti-CD22 antibody) in 64 patients with relapsed/refractory NHL, including 17 patients who underwent prior autologous stem-cell transplantation (ASCT). Objective (OR) and complete responses (CR/complete response unconfirmed [CRu]), as well as progression-free survival (PFS), were determined. Results At the maximum total 90Y dose of 45 mCi/m2 (1,665 MBq/m2), grade 3 to 4 hematologic toxicities were reversible to grade 1 in patients with less than 25% bone marrow involvement. The overall OR rate and median PFS for all 61 evaluable patients was 62% (CR/CRu, 48%) and 9.5 months, respectively. Patients without prior ASCT obtained high OR rates of 71% (CR/CRu, 55%) across all NHL subtypes and 90Y doses, even in poor-risk categories (refractory to last anti-CD20–containing regimen, 73% [CR/CRu, 60%]; bulky disease: 71% [CR/CRu, 43%]). Patients with prior ASCT received lower doses, but achieved an OR rate of 41% (CR/CRu, 29%). For patients with follicular lymphoma (FL), OR rates and median PFS increased with total 90Y-dose, reaching 100% (CR/CRu, 92%) and 24.6 months, respectively, at the highest dose levels (> 30 mCi/m2 total 90Y-dose [1,110 MBq/m2]). Further, patients with FL refractory to prior anti-CD20–containing regimens achieved 90% (nine of 10 patients) OR and CR/CRu rates and a median PFS of 21.5 months. Conclusion Fractionated anti-CD22 radioimmunotherapy provides high total doses of 90Y, yielding high rates of durable CR/CRus in relapsed/refractory NHL, resulting in 20 mCi/m2 × 2 weeks as the recommended dose for future studies.
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Long-Acting Methylphenidate for Cancer-Related Fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial
Authors: Moraska Amanda R. , Sood Amit , Dakhil Shaker R. , Sloan Jeff A. , Barton Debra , Atherton Pamela J. , Suh Jason J. , Griffin Patricia C. , Johnson David B. , Ali Aneela , Silberstein Peter T. , Duane Steven F. , Loprinzi Charles L. 
Published: July 2010

PurposeFatigue is one of the most common symptoms experienced by patients with cancer. This trial was developed to evaluate the efficacy of long-acting methylphenidate for improving cancer-related fatigue and to assess its toxicities.Patients and MethodsAdults with cancer were randomly assigned in a double-blinded manner to receive methylphenidate (target dose, 54 mg/d) or placebo for 4 weeks. The Brief Fatigue Inventory was the primary outcome measure, while secondary outcome measures included a Symptom Experience Diary (SED), the Short Form-36 (SF-36) Vitality Subscale, a linear analog self-assessment, the Pittsburgh Sleep Quality Index, and the Subject Global Impression of Change.ResultsIn total, 148 patients were enrolled. Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35). Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative. However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02). There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.ConclusionThis clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia
Authors: Corbacioglu Andrea , Scholl Claudia , Schlenk Richard F. , Eiwen Karina , Du Juan , Bullinger Lars , Fröhling Stefan , Reimer Peter , Rummel Mathias , Derigs Hans-Günter , Nachbaur David , Krauter Jürgen , Ganser Arnold , Döhner Hartmut , Döhner Konstanze 
Published: July 2010

PurposeTo evaluate the prognostic impact of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) expressing the CBFB-MYH11 fusion transcript.Patients and MethodsQuantitative reverse transcriptase polymerase chain reaction (PCR) was performed on 684 bone marrow (BM; n = 331) and/or peripheral blood (PB; n = 353) samples (median, 13 samples per patient) from 53 younger adult (16 to 60 years old) patients with AML treated in prospective German-Austrian AML Study Group treatment trials. Samples were obtained at diagnosis (BM, n = 45; PB, n = 48), during treatment course (BM, n = 153; PB, n = 122), and at follow-up (BM, n = 133; PB, n = 183). To evaluate the applicability of PB for MRD detection, 198 paired BM and PB samples obtained at identical time points were analyzed.ResultsThe following three clinically relevant checkpoints were identified during consolidation and early follow-up that predicted relapse: achievement of PCR negativity in at least one BM sample during consolidation therapy (2-year relapse-free survival [RFS], 79% v 54% for PCR positivity; P = .035); achievement of PCR negativity in at least two BM or PB samples during consolidation therapy and early follow-up (≤ 3 months; 2-year RFS, P = .001; overall survival, P = .01); and conversion from PCR negativity to PCR positivity with copy ratios of more than 10 after consolidation therapy. Analysis of paired BM and PB samples revealed BM samples to be more sensitive during the course of therapy, whereas for follow-up, PB samples were equally informative.ConclusionWe defined clinically relevant MRD checkpoints that allow for the identification of patients with CBFB-MYH11–positive AML who are at high risk of relapse. Monitoring of CBFB-MYH11 transcript levels should be incorporated into future clinical trials to guide therapeutic decisions.
Photocatalytic and Antibacterial Activities over WO3 on Glass Filters
Authors: Sayama Kazuhiro , Hayashi Hiroki , Konishi Yoshiya , Gunji Takahiro , Sugihara Hideki 
Published: July 2010

Abstract
WO3 on a glass filter prepared from peroxotungstic acid (PA) showed not only high photocatalytic activity under solar simulated light but also high antibacterial activity even if light irradiation was not present.
A Simple and Convenient Method to Fabricate Hexagonally Ordered Gold Nanoparticle Arrays Using Diblock Copolymer Micelle Template
Authors: Watanabe Shigeru , Nakano Shin , Imai Chie , Laskar Inamur R , Komura Tomonori , Hadano Shingo , Iyoda Tomokazu 
Published: July 2010

Abstract
Monolayer films of hexagonally ordered diblock copolymer micelles were prepared as templates by self-assembly. Gold nanoparticles immediately self-assembled on each individual micelle upon immersion of the template in an aqueous solution of the nanoparticles. This provided a simple, convenient, and inexpensive nanofabrication technique for manufacturing ordered arrays of gold nanoparticles over an extended area.
Hepcidin concentrations and iron homeostasis in preeclampsia
Authors: Toldi Gergely , Stenczer Balázs , Molvarec Attila , Takáts Zoltán , Bekő Gabriella , Rigó János , Vásárhelyi Barna 
Published: July 2010

Abstract

Background: Plasma iron is increased in preeclampsia (PE) when compared to healthy pregnant women. This is in contrast to inflammation characteristic for PE. The link between iron homeostasis and inflammation is hepcidin. Our goal was to describe hepcidin concentrations and its association with iron homeostasis in PE.

Methods: We obtained peripheral blood samples from 30 preeclamptic [gestational age: 36.5 (24–40) weeks] and 37 healthy pregnant women [gestational age: 36 (28–39) weeks] to determine plasma hepcidin and interleukin-6 (IL-6) concentrations, complete blood cell counts and parameters of iron homeostasis [plasma iron, transferrin and ferritin levels and total iron binding capacity (TIBC)]. Hepcidin was measured using mass spectrophotometry. The Mann-Whitney test was used for statistical analysis.

Results: Plasma hepcidin, IL-6, iron and ferritin concentrations were increased (p<0.05 for all), whereas plasma transferrin, TIBC and mean corpuscular hemoglobin concentrations were lower (p<0.05 for all) in PE compared to healthy pregnant women. No differences were seen in the other parameters investigated.

Conclusions: Plasma iron concentrations are increased despite high hepcidin concentrations in PE. This might indicate a resistance to the iron-decreasing action of hepcidin.
Clin Chem Lab Med 2010;48:1423–6.
Using cationic polyvinyl alcohol (C-PVA) to improve the strength of wood-free papers containing high-yield pulp (HYP)
Authors: Liu Xin , Fatehi Pedram , Ni Yonghao , Xiao Huining 
Published: July 2010

AbstractHigh-yield pulp (HYP) is gaining increasing interest in wood-free papers, because it can improve the bulk, formation, and opacity of papers. However, one of the challenges for the papermakers is the strength of papers when a large amount of HYP is replaced with hardwood kraft pulp. In this work, we explored the potential of using cationic-modified polyvinyl alcohol (C-PVA) in increasing the strength properties of HYP. Also, C-PVA was applied to the paper-sheets made of softwood/hardwood bleached kraft pulps (SBKP/HBKP) and HYP under various conditions, and the corresponding paper properties were evaluated. It was observed that C-PVA increased the strength properties of these paper-sheets, and the results obtained from using C-PVA were only slightly less effective than those obtained from using cationic starch (C-starch). Furthermore, the addition of C-PVA to HYP, and subsequently mixing with the blend of SBKP/HBKP (option no. 1) improved the tensile and burst indices, light scattering coefficient and apparent density of paper-sheets more significantly than did the addition of C-PVA directly to the mixed furnish of SBKP/HBKP/HYP (option no. 2). Additionally, atomic force microscope (AFM) analysis showed that the attraction force, developed between the AFM-tip and the fiber surface, was changed by the C-PVA modification. The tensile and burst indices of paper-sheets were improved by adding 10 mg g-1C-PVA and substituting 30% of HYP for HBKP, whereas the tear index, apparent density, PPS-roughness, and brightness decreased.